GRAL GRAIL, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1699031 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY0.0%
TTM EPS YoY13.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-347.3%
Net margin-243.8%
FCF margin-187.3%
EBITDA margin-337.4%
Returns
ROE-17.3%
ROA-15.2%
ROIC (approx.)-20.1%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio8.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20232023-01-01 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $147.17M | $125.59M | $93.11M | $55.55M |
| R&D expense | $195.79M | $322.38M | $338.75M | $329.58M |
| SG&A expense | $159.10M | $213.86M | $200.27M | $174.11M |
| Operating income | -$562.16M | -$2.19B | -$1.52B | -$5.44B |
| Pretax income | -$534.50M | -$2.16B | -$1.51B | -$5.44B |
| Income tax | -$126.15M | -$135.36M | -$41.95M | -$42.29M |
| Net income | -$408.35M | -$2.03B | -$1.47B | -$5.40B |
| EBITDA | -$544.15M | -$2.17B | -$1.50B | -$5.43B |
| EPS (basic) | -11.11 | -63.54 | -47.21 | -173.89 |
| EPS (diluted) | -11.11 | -63.54 | -47.21 | -173.89 |
| Weighted avg. shares (diluted) | 36.75M | 31.90M | 31.05M | 31.05M |
| Balance sheet | ||||
| Cash & equivalents | $249.73M | $217.58M | $97.29M | $241.60M |
| Receivables | $18.30M | $20.31M | $16.94M | — |
| Current assets | $953.85M | $819.86M | $156.06M | — |
| PP&E, net | $51.81M | $69.06M | $85.00M | — |
| Goodwill | — | $0 | $888.94M | $1.50B |
| Intangibles | $1.85B | $2.02B | $2.69B | — |
| Total assets | $2.92B | $2.98B | $3.91B | — |
| Current liabilities | $79.67M | $76.92M | $163.61M | — |
| Total liabilities | $344.15M | $479.90M | $267.63M | — |
| Shareholders' equity | $2.58B | $2.50B | — | — |
| Shares outstanding | 40.33M | 33.89M | 0 | — |
| Cash flow statement | ||||
| Operating cash flow | -$299.01M | -$577.16M | -$595.80M | -$561.31M |
| Capital expenditure | $909,000 | $5.21M | $12.89M | $22.86M |
| Free cash flow | -$299.92M | -$582.36M | -$608.69M | -$584.17M |
| Investing cash flow | -$85.05M | -$551.01M | -$12.89M | -$22.86M |
| Financing cash flow | $423.32M | $1.24B | $463.77M | $604.82M |
| Depreciation & amortization | $18.01M | $19.72M | $20.36M | $16.43M |
| Stock-based compensation | $58.28M | $86.08M | $97.23M | $75.73M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.